KLOW peptide: what each drug did on its own
KPV, GHK-Cu, BPC-157, and TB-500 share one research vial. Each is a short protein chain with studies of its own.
The short version: why researchers made the mix
Researchers put KPV, GHK-Cu, BPC-157, and TB-500 together because repair has several steps. Animal and dish work supplied most of that hope, yet none of the four drugs has FDA approval for people, and the full KLOW mix has never faced a direct comparison. Each claim therefore traces to one drug, never all four together. KPV calmed parts of the immune response that cause swelling. GHK-Cu supplied copper and helped the body make collagen, the protein that lends strength to skin and tendons. BPC-157 helped small blood vessels grow in animals and cells. TB-500 helped cells move across a wound in studies. The four effects might fit together, but no study shows that they do inside your body. The KLOW effects page explains how you can weigh the findings against the risks.
What is KLOW peptide, in everyday words?
KLOW peptide is a blend made from four short protein chains. A common vial holds 80 mg in all. GHK-Cu makes up 50 mg. BPC-157, or Body Protection Compound 157, is a 15-amino-acid chain, meaning a row of protein parts, and makes up 10 mg. TB-500 comes from a larger protein called thymosin beta-4 and makes up 10 mg. KPV makes up the last 10 mg. Water leaves the drugs together as a liquid; they don't combine into a fifth drug. There is no FDA-approved KLOW product, and no standard drug book lists one. Research-labelled KLOW remains on sale, while injectable prescription access calls for a clinician's decision. KLOW also isn't a GLP-1 drug, the kind used for blood sugar and weight loss. The goal was research on repair and swelling, not proof that either problem improves in people. Keep that limit beside any claim about your knee, your skin, or your tendon.
What the KLOW peptide blend might change
Researchers hoped each drug in the KLOW peptide blend might handle a different part of repair. KPV can calm the body's swelling response. GHK-Cu supplies copper and helps make collagen. BPC-157, or Body Protection Compound 157, led to more new blood vessels in animals and cells [8]. GHK-Cu also made blood-vessel cells multiply in separate work [11]. Full thymosin beta-4, the protein behind TB-500, helped rodent wounds form vessels [9]. New vessels carry blood into hurt tissue, while collagen gives the tissue support. Both effects may sound useful for your sore knee or tendon. Your body would clear the four drugs at unequal rates, so their blood levels wouldn't stay even. TB-500 also has far less study than full thymosin beta-4. No person, animal, or dish has received the four-drug product in a study. The blend gives researchers a question, not you an answer about your joint.
What KLOW adds that GLOW leaves out
KLOW isn't the same mix as GLOW or WOLVERINE. GLOW has GHK-Cu, BPC-157, and TB-500, but it leaves out KPV. WOLVERINE uses other parts. KPV is the main change between KLOW and GLOW. It is cut from a hormone, which is a message the body sends. In immune cells and cells from the gut, KPV slowed some of the body's calls for swelling. One such call carries the lab number 6; you don't need that label to grasp the result. Swollen gut cells also drew KPV inside when their liquid held about 160 micromolar, a lab measure of the liquid's strength [3]. That figure isn't an amount for you to take. Mice and cells in dishes supplied the finding; people taking KLOW did not. KLOW's claim about swelling therefore depends mostly on KPV work. GLOW has no KPV. The klow stack page lets you compare all four drugs.
What each drug changed while tissue repaired
Three KLOW drugs led to new vessel growth in separate studies. BPC-157 made blood-vessel cells respond to a growth message. The paper called the receiving spot receptor 2, meaning the place where a cell catches that message. Rats then grew more small vessels and regained blood flow to an injured leg faster [8]. GHK-Cu comes from a natural protein part that holds copper. In cells and animals, similar copper-holding parts made blood-vessel cells multiply [11]. TB-500 is based on a larger body protein. Full thymosin beta-4 helped rodent wounds, hair roots, and vessels [9]. In a 2025 study, a wet dressing carried full thymosin beta-4 while wounds formed more vessels [14]. These findings explain the interest, but none tested KLOW or showed the mix can heal your knee, skin, or tendon. The KLOW research page shows you which drug belongs beside each result.